ライフサイエンスコーパス: cancer vaccine

1 n allogeneic whole-cell therapeutic prostate cancer vaccine.

2 improve the efficacy of an experimental anti-cancer vaccine.

3 ial use of grp170-secreting tumor cells as a cancer vaccine.

4 erred in combination with high-dose IL-2 and cancer vaccine.

5 chemically induced mouse tumor and develop a cancer vaccine.

6 ld point the way to an effective therapeutic cancer vaccine.

7 mits or alters its efficacy as a therapeutic cancer vaccine.

8 UC1 may be a promising candidate as a breast cancer vaccine.

9 cells and IL-2 can augment the function of a cancer vaccine.

10 romising target candidates for a therapeutic cancer vaccine.

11 ruct capable of functioning as a therapeutic cancer vaccine.

12 reenergize ACT (ReACT) with a pathogen-based cancer vaccine.

13 d the late-stage clinical trials of a breast cancer vaccine.

14 s protein may serve as a rational target for cancer vaccines.

15 reater therapeutic efficacy of peptide-based cancer vaccines.

16 us improve the antitumor efficacy of current cancer vaccines.

17 ivated T cells and natural killer cells, and cancer vaccines.

18 tating the rational design of more effective cancer vaccines.

19 well as an immune target for development of cancer vaccines.

20 olved in tumor spread and glycopeptide-based cancer vaccines.

21 on, as DC-targeted adjuvants for intradermal cancer vaccines.

22 tion can greatly impact the effectiveness of cancer vaccines.

23 form to generate "off-the-shelf" therapeutic cancer vaccines.

24 aid in the development of such personalized cancer vaccines.

25 f antibody therapy and usher in a new era of cancer vaccines.

26 ritical for enabling routine clinical use of cancer vaccines.

27 duce the next generation of highly efficient cancer vaccines.

28 ials showing benefit to the patients revived cancer vaccines.

29 g adjuvant in the development of therapeutic cancer vaccines.

30 ble for the design of common "off-the-shelf" cancer vaccines.

31 nsideration for designing safe and effective cancer vaccines.

32 Cs and substantially enhanced the effects of cancer vaccines.

33 (CTLs) underpins the success of therapeutic cancer vaccines.

34 hopefully ending the Kafkaesque futility of cancer vaccines.

35 he MAGE-3 ASCI has also revived the field of cancer vaccines.

36 rs and are promising targets for therapeutic cancer vaccines.

37 ule as an effective component of therapeutic cancer vaccines.

38 nologic and therapeutic activity of DC-based cancer vaccines.

39 targets for personalized medicine, including cancer vaccines.

40 ueling controversy over the utility of human cancer vaccines.

41 ations of this work for developing effective cancer vaccines.

42 ould be modulated to improve the response to cancer vaccines.

43 should be important for developing molecular cancer vaccines.

44 ion for the further development of efficient cancer vaccines.

45 are potential targets for the development of cancer vaccines.

46 ages over other antigen delivery systems for cancer vaccines.

47 y have direct implications for the design of cancer vaccines.

48 ld be tested in therapeutic combination with cancer vaccines.

49 at may have implications in designing future cancer vaccines.

50 expressing tumors and for the development of cancer vaccines.

51 xes have clinical significance as autologous cancer vaccines.

52 it an appropriate candidate to combine with cancer vaccines.

53 es for the development of safe and effective cancer vaccines.

54 were synthesized and screened as therapeutic cancer vaccines.

55 ble and possibly clinically useful DNA-based cancer vaccines.

56 to the development of effective therapeutic cancer vaccines.

57 nt candidates for the development of generic cancer vaccines.

58 immunosurveillance and improves responses to cancer vaccines.

59 surface antigens and hence, as multifaceted cancer vaccines.

60 be utilized to develop functional conjugate cancer vaccines.

61 and potentially tune the immune response to cancer vaccines.

62 Cs) has been proposed for the preparation of cancer vaccines.

63 It contributes greatly to the failure of cancer vaccines.

64 open an opportunity to improve the effect of cancer vaccines.

65 approach for the design of protein-targeted cancer vaccines.

66 can have a broad impact on the design of new cancer vaccines.

67 to discover them may be useful in developing cancer vaccines.

68 g autoimmunity, with possible application in cancer vaccines.

69 ryl lipid A (MPLA) to form novel therapeutic cancer vaccines.

70 es essential for the therapeutic efficacy of cancer vaccines.

71 observations are of value for the design of cancer vaccines.

72 le platform for the development of effective cancer vaccines.

73 de the design of next-generation therapeutic cancer vaccines.

74 st, have been the major focus of therapeutic cancer vaccines.

75 significant interest for the development of cancer vaccines.

76 an effective platform for the development of cancer vaccines.

77 e microenvironments that create barriers for cancer vaccines.

78 a powerful new adjuvant system for TAA-based cancer vaccines.

79 We will highlight current results with cancer vaccines, adoptive T-cell therapy and immunomodul

80 ies include antitumor monoclonal antibodies, cancer vaccines, adoptive transfer of ex vivo activated

81 ion, dramatically enhances the activity of a cancer vaccine against liver metastases but not metastas

82 instrumental to the development of the first cancer vaccines against cancers having an infectious eti

83 will facilitate the development of effective cancer vaccines against prostate cancer.

84 Cancer vaccines aim at inducing (a) tumor-specific effec

85 show genetic regulation of the response to a cancer vaccine and an unequal effect of removing CD25(hi

86 with a mechanistic understanding of ongoing cancer vaccine and cellular immunotherapy clinical trial

87 ted therapeutic markers may inform effective cancer vaccine and checkpoint blockade therapies.

88 n shown to enhance the anti-tumor effects of cancer vaccines and adoptive cell therapy.

89 Here, we tested in mice several cancer vaccines and an adoptive T cell transfer approach

90 designed to enhance this capacity, including cancer vaccines and coinhibitory receptor blockade, have

91 cuss the immunological basis for therapeutic cancer vaccines and how the current understanding of den

92 se III human clinical trials as adjuvants to cancer vaccines and in combination with conventional che

93 human clinical trials as an adjuvant to anti-cancer vaccines and in combination with other therapies.

94 ic T-cell immunity: active immunisation with cancer vaccines and infusion of competent T cells via ad

95 rational basis for the combinatorial use of cancer vaccines and local tumor irradiation.

96 mmunotherapeutic strategy based on synthetic cancer vaccines and metabolic engineering of TACAs on tu

97 Y-SAR-35 is therefore a potential target for cancer vaccines and monoclonal antibody-based immunother

98 ecific to the tumour that can be targets for cancer vaccines and T cell therapies is a challenge.

99 itable for the evaluation and development of cancer vaccines and therapeutics.

100 ression in the dendritic cells (DCs) used as cancer vaccines and to enhance their responsiveness to l

101 mimics may contribute to the development of cancer vaccines and to the improvement of cancer diagnos

102 These materials show promise as cancer vaccines, and more broadly suggest that polymers

103 the potential to revolutionize the field of cancer vaccines, and provide patients with a vaccine in

104 clinical application of currently available cancer vaccine approaches is based more on surrogate end

105 clophosphamide in targeting Tregs to augment cancer vaccine approaches.

106 Personalized cancer vaccines are a promising approach for inducing T

107 Cancer vaccines are beginning to show signs of clinical

108 gh rates of objective clinical response when cancer vaccines are combined with chemotherapy in patien

109 Personalized cancer vaccines are emerging as one of the most promisin

110 mption that the optimal peptide antigens for cancer vaccines are high-affinity MHC ligands.

111 Cancer vaccines are in early murine and clinical precanc

112 Although cancer vaccines are in the clinic, several issues remain

113 However, current HCC cancer vaccines are mostly based on native shared-self/t

114 s of B-cell depletion on immune responses to cancer vaccines are unknown.

115 ith fewer recurrences, suggesting a role for cancer vaccines as adjuvant therapy.

116 tractive candidate adjuvants for therapeutic cancer vaccines as they can induce a balanced humoral an

117 1) is considered as a potential target for a cancer vaccine, as it is overexpressed in many malignant

118 e p373-382 is a candidate epitope for breast cancer vaccines, as it is processed by proteasomes and b

119 We have constructed a novel breast cancer vaccine, Bacillus Calmette-Guerin (BCG)-hIL2MUC1,

120 ell surface, the development of personalized cancer vaccines based on IR-derived neoepitopes should b

121 ation has motivated the interest in personal cancer vaccines based on sequencing the patient's tumor

122 d therapeutic options for ER-negative breast cancers, vaccines based on CT-X antigens might prove to

123 alogue poly(I:C) is a promising adjuvant for cancer vaccines because it activates both dendritic cell

124 broad implications for many of the DC-based cancer vaccines being developed for clinical application

125 an important consideration in the design of cancer vaccines, but factors affecting selection are not

126 stic approach for the development of generic cancer vaccines, but the potential of this type of vacci

127 We formulated an IFNgamma-inducing cancer vaccine called TEGVAX that combined GM-CSF and mu

128 Therapeutic cancer vaccines can be effective for treating patients,

129 e sufficient data to support the notion that cancer vaccines can induce anti-tumor immune responses i

130 Cancer vaccines can induce the in vivo generation of tum

131 Immunization with effective cancer vaccines can offer a much needed adjuvant therapy

132 tion has progressed from being an attractive cancer vaccine candidate to recognition as a key player

133 C-maturation stimulus, making it a potential cancer vaccine candidate.

134 at activate T-cells indicating that they are cancer vaccine candidates.

135 by dendritic cells (DC) make them attractive cancer vaccine candidates.

136 pherical nucleic acids (SNAs) functioning as cancer-vaccine candidates.

137 A therapeutic polyvalent cancer vaccine (Canvaxin vaccine; CancerVax Corp, Carlsb

138 We completed the first prophylactic cancer vaccine clinical trial based on a non-viral antig

139 entially making it a more potent therapeutic cancer vaccine compared with existing MAGE-A3 protein an

140 binatorial use of CD40 and TLR agonists as a cancer vaccine, compared with monotherapy, elicits high

141 HAPa is a cancer vaccine consisting of allogeneic pancreatic cance

142 viously reported a clinical trial of a human cancer vaccine consisting of autologous tumor cells modi

143 this potential, we have developed cell-based cancer vaccines consisting of tumor cells expressing syn

144 urium-NY-ESO-1) was shown to be an efficient cancer vaccine construct in mice and to stimulate NY-ESO

145 ses induced by PROSTVAC-VF, a poxvirus-based cancer vaccine currently in phase III clinical trials.

146 Effective cancer vaccines deliver concentrated antigen to both HLA

147 enefits of these cylindrical nano-vectors as cancer vaccine delivery systems as well as the obstacles

148 ynthetic peptides are an established mode of cancer vaccine delivery, but generating the peptides for

149 peutic noncellular (vector-based or subunit) cancer vaccines, dendritic cell vaccines, engineered T c

150 of cognate CD4+ T cell help is important for cancer vaccine design and provides the rationale for a p

151 iers are important considerations in mucosal cancer vaccine design.

152 discussed within the context of MUC1 breast cancer vaccine design.

153 Cancer vaccines designed to elicit an antibody response

154 sing a DNA vaccine have implications for all cancer vaccines designed to induce and maintain antibody

155 therefore, have implications on the DC-based cancer vaccine designs and are relevant in the inquiry i

156 istance of tumor recurrences to conventional cancer vaccines despite small tumor size, an intact anti

157 is Ag and thus represents a prime target for cancer vaccines, despite infrequent natural occurrence o

158 most effective when used to prevent disease, cancer vaccine development has focused predominantly on

159 er cells and therefore, a good candidate for cancer vaccine development.

160 g-term competent CTL necessary for tumor and cancer vaccine development.

161 ion system is a promising novel strategy for cancer vaccine development.

162 ride antigen, seriously hinders its usage in cancer vaccine development.

163 and micrometastases would be an advantage in cancer vaccine development.

164 yte activation, and differentiation in human cancer vaccine development.

165 markers, and their structural utility in new cancer vaccine development.

166 Our data suggest a new potential approach to cancer vaccine development.

167 might soon enhance the efficacy of existing cancer vaccines directed against a variety of malignanci

168 s suggest that PD-1 blockade enhances breast cancer vaccine efficacy by altering both CD8 T cell and

169 f TLR adjuvants systemically boosts DC-based cancer vaccine efficacy, it could also increase toxicity

170 ression continues to be a major inhibitor of cancer vaccine efficacy, we examined in this study wheth

171 s in enhancing antitumor immune response and cancer vaccine efficacy.

172 Nous-209 is an "off-the-shelf" cancer vaccine encoding many neoantigens shared across s

173 targeting Listeria monocytogenes (LM) with a cancer vaccine enhanced the antitumor effect of vaccine-

174 mor cell escape from immune surveillance and cancer vaccine failure.

175 pe-enhanced peptide may serve as a candidate cancer vaccine for HLA-B7+ patients with alveolar rhabdo

176 ng rationale for combining immunotoxins with cancer vaccines for the treatment of patients with advan

177 The recent approval of a prostate cancer vaccine has renewed hope for anticancer immunothe

178 The clinical benefit of therapeutic cancer vaccines has been established.

179 ntigens and their application in therapeutic cancer vaccines has not yet resulted in a successful the

180 Efficacious cancer vaccines have been a challenge because they are b

181 ells for priming adaptive immunity, DC-based cancer vaccines have been largely insufficient to effect

182 In clinical trials, cancer vaccines have been less effective at priming T ce

183 Globo H-based therapeutic cancer vaccines have been tested in clinical trials for

184 Overall, cancer vaccines have had a record of failure as an adjuv

185 Whereas cancer vaccines have prevented the growth of tumors, it

186 generated from the preclinical evaluation of cancer vaccines have resulted in the initiation of clini

187 Therapeutic cancer vaccines have shown activity in metastatic castra

188 e 1 and 2 trials of PANVAC, a poxviral-based cancer vaccine, have suggested clinical efficacy in some

189 by comparing microarrays of cellular breast cancer vaccines highly enriched for cells that induced b

190 Cancer vaccines hold great promise for improved cancer t

191 Cancer vaccines hold great promise to produce antigen-sp

192 Cancer vaccines hold much promise; however, many unresol

193 nanotechnology in the development of in situ cancer vaccines, immune checkpoint inhibitors, adoptive

194 (ICD), are known to be a potential source of cancer vaccine immunogen.

195 tic approaches currently used in the clinic: cancer vaccines, immunostimulatory agents, adoptive T ce

196 been tested in previous clinical trials for cancer vaccine immunotherapy, yet resulted in limited th

197 ent challenges to manufacturing personalized cancer vaccines in an optimal format for inducing antica

198 nd, as demonstrated here, may have impact as cancer vaccines in particular.

199 lls (DC-TC) are currently being evaluated as cancer vaccines in preclinical models and human immuniza

200 be very useful in enhancing the efficacy of cancer vaccines in the face of tumor immune suppression.

201 de to develop new antigens for the design of cancer vaccines in the near future.

202 bination of ATRA with two different types of cancer vaccines in two different tumor models significan

203 In this study, we used polymeric cancer vaccines incorporating different classes of adjuv

204 In mice, administration of a cancer vaccine increased PD-1 on T cells with concomitan

205 immunogenic tumors and, in combination with cancer vaccines, increases the rejection of poorly immun

206 Most cancer vaccines induce CTL responses to tumor-associated

207 Current cancer vaccines induce tumor-specific T cell responses w

208 To understand why cancer vaccine-induced T cells often do not eradicate tu

209 Efficacy of dendritic cell (DC) cancer vaccines is classically thought to depend on thei

210 The in vivo therapeutic efficacy of DC-based cancer vaccines is limited by suboptimal DC maturation p

211 The difficulty in developing prophylactic cancer vaccines is primarily due to the fact that tumor

212 A major problem with current cancer vaccines is that the induction of CD8 immune resp

213 Ineffective responses to cancer vaccines may be caused, in part, by low numbers o

214 Optimum efficacy of therapeutic cancer vaccines may require combinations that generate e

215 Cancer vaccines may thus need to readjust the imbalance

216 ith adoptive T-cell therapies or therapeutic cancer vaccines, may prove to be more efficient in prolo

217 Cancer vaccines not only need to induce a robust tumor A

218 Engineered cancer vaccines offer a promising approach for inducing

219 revention through chemoprevention agents and cancer vaccines offers significant promise for reducing

220 an immunomodulator to enhance the effect of cancer vaccines or adoptive cell transfer therapy.

221 and suggest HERV-K as a possible target for cancer vaccines or immunotherapy against this highly agg

222 ficant impact on the therapeutic efficacy of cancer vaccines or other immune-based therapies.

223 steria monocytogenes is being developed as a cancer vaccine platform because of its ability to induce

224 emase complementation system to our Listeria cancer vaccine platform.

225 itation of nano-vaccinology to intensify the cancer vaccine potency may overcome the need for adminis

226 antigen-presenting cells in vivo to enhance cancer vaccine potency.

227 tly met with clinical success, and the first cancer vaccine received U.S. Food and Drug Administratio

228 istory of targeting embryonal tissues toward cancer vaccines, recent identification of crucial stemne

229 Cancer vaccine regimens use various strategies to enhanc

230 iveness of L. monocytogenes as a recombinant cancer vaccine remains intact.

231 The development of effective cancer vaccines remains an urgent, but as yet unmet, cli

232 The development of cancer vaccines requires approaches to induce expansion

233 allenge in the ability to mount an effective cancer vaccine response.

234 , the king tapped Samir Khleif, chief of the cancer vaccine section at the US National Cancer Institu

235 results suggest that clinical protocols for cancer vaccines should be designed to avoid exposing res

236 Cancer vaccines should preferably be composed of multipl

237 servations, different DCs clinically used as cancer vaccines show different Treg-recruiting abilities

238 , in combination with a dendritic cell-based cancer vaccine significantly augments vaccine efficacy i

239 New cancer vaccine strategies are required to vanquish the s

240 ssue-specific, and it offers a rationale for cancer vaccine strategies targeting tissue-restricted tu

241 opment of highly effective immunotherapeutic cancer vaccine strategies using engineered uracil auxotr

242 gens can expand Tregs, posing a challenge to cancer vaccine strategies.

243 Ags by exosomes is under consideration as a cancer vaccine strategy; however, we found that pretreat

244 ere, we report the findings of a preclinical cancer vaccine study demonstrating vaccine-dependent PDL

245 Importantly for their application as cancer vaccines, such DC1s stably retained their type 1

246 umor phenotype may predict for resistance to cancer vaccines, suggesting a possible predictive biomar

247 When combined with IL-13Ralpha2 DNA cancer vaccine, surprisingly, it mediated synergistic an

248 se approaches include but are not limited to cancer vaccine systems utilizing novel type I interferon

249 ncer, and implicates SPAG5 as an alternative cancer vaccine target in multiple cancers.

250 shaping the immune response to multiepitope cancer vaccines targeting p53.

251 Personalized cancer vaccines targeting patient-specific neoantigens a

252 odified vaccine and may be relevant to other cancer vaccine technologies.

253 ress has been made, but we do not yet have a cancer vaccine that can reliably and consistently induce

254 Nevertheless, cancer vaccines that aim to expand such CD8(+) T cells i

255 opment of a new class of recombinant protein cancer vaccines that deliver different CD8(+) and CD4(+)

256 nanoscale constructs as potential synthetic cancer vaccines that generate significant titers of anti

257 duction of an efficacious immune response by cancer vaccines that solely provide more antigen to an a

258 Despite the initial excitement over cancer vaccines, the clinical effectiveness of immunothe

259 te the tremendous potential of peptide-based cancer vaccines, their efficacy has been limited in huma

260 Cancer vaccine therapies have only achieved limited succ

261 rom immunosuppression toward potentiation of cancer vaccine therapies.

262 ponses mediated by T cells in the setting of cancer vaccine therapy.

263 ool for improving the potency of therapeutic cancer vaccines through the efficient induction of NK ce

264 For a targeted cancer vaccine to be effective, the antigen of interest

265 this immune mechanism to create a whole cell cancer vaccine to treat melanoma tumors.

266 cells needs to be considered when designing cancer vaccines to ensure full potential of the treatmen

267 lain the dissociation between the ability of cancer vaccines to induce high numbers of tumor-specific

268 The ability of cancer vaccines to induce tumor-specific CD8+ T cells in

269 rently being evaluated in clinical trials as cancer vaccines to induce tumor-specific immune response

270 , we can drive a concerted effort focused on cancer vaccines to reprogram the immune response to prev

271 ort the use of PD-1 and Tim-3 blockades with cancer vaccines to stimulate potent antitumor T-cell res

272 erefore urgently needed for patient-specific cancer vaccines to succeed in the clinic.

273 within a tumor will likely be necessary for cancer vaccines to trigger an effective antitumor respon

274 Most cancer vaccines, to date, fail to control established tu

275 Cancer vaccines, to date, have shown limited effect to c

276 We consider here results in cancer vaccine trials and highlight alternate strategies

277 Cancer vaccine trials have failed to yield robust immune

278 In this short time span, outcomes of cancer vaccine trials have raised hopes and also surface

279 rial vaccines to achieve maximal efficacy in cancer vaccine trials in humans.

280 In our cancer vaccine trials of 440 patients, the objective res

281 responses, our data provide a rationale for cancer vaccine trials with peptides derived from the NY-

282 They also support the relevance of cancer vaccine trials with peptides NY-ESO-1 87-111 in t

283 be useful not only for immune monitoring of cancer vaccine trials, but also for adoptive cellular im

284 ide/IFA), which is commonly used in clinical cancer vaccine trials.

285 , a cancer-testis Ag widely used in clinical cancer vaccine trials.

286 oth the onset and the monitoring of upcoming cancer-vaccine trials using SSX-derived immunogens.

287 Cancer vaccines typically depend on cumbersome and expen

288 to that achieved by a virotherapy-associated cancer vaccine using a recombinant oncolytic vaccinia vi

289 Therapeutic cancer vaccines using ex vivo engineered or in vivo targ

290 We synthesized HER2-based cancer vaccines using three icosahedral plant viruses as

291 ever, CMV has been increasingly studied as a cancer vaccine vector, and multiple groups, including ou

292 ndosomal origin and are considered potential cancer vaccine vectors.

293 de) (PNSN), and to assess their potential as cancer vaccine vectors.

294 e potential of SOX-4 for broad use as a lung cancer vaccine, we have evaluated the expression of SOX-

295 -KLH are promising candidates as therapeutic cancer vaccines, whereas fully synthetic GM2-MPLA, which

296 attractive candidates for broadly applicable cancer vaccines, which could combine multiple tumor epit

297 iven of how future biomaterial-based mucosal cancer vaccines will be shaped by new discoveries in muc

298 men using VISTA blockade and a peptide-based cancer vaccine with TLR agonists as adjuvants.

299 istic rationale to combine IFNgamma-inducing cancer vaccines with immune checkpoint blockade.

300 d in vivo for their potential as therapeutic cancer vaccines yielding promising therapeutic results f